Skip to main content
. 2022 Aug 30;12:939118. doi: 10.3389/fonc.2022.939118

Table 3.

Summary of clinical and laboratory measurements.

Patient Dose Erlotinib (mg) Duration Treatment Planned Duration Treatment Received Neck CT% change in max. diameter Day of Early In-Treatment PET/CT Early In-Treatment PET/CT % change in SUV Post-treatment PET/CT % change in SUV Erlotinib (ng/mL) OSI-420 (ng/mL)
1 150 17 17 -37 7 -26 -26 NIA N/A
2 150 20 20 -28 6 -28 -10 3407.6 82.75
3 150 14 14 -22 4 -27 -43 7520.85 533.1
4 150 15 15 -21 6 -38 -55 NIA N/A
5 150 21 21 -21 6 -52 -37 113.95 2.65
6 150 26 26 -16 6 -32 -40 1635.35 83.25
7 150 14 11 -13 6 -13 NIA NIA N/A
8 150 14 14 -10 6 -27 -12 163ll.15 22.5
9 150 18 18 0 6 5 +9 706.85 14.65
10 300 27 27 -45 6 -43 -70 6023.4 166.05
11 300 15 15 -27 5 -70 -65 3753.15 46.25
12 300 22 20 -25 6 -39 -49 325.8 0.5
13 300 18 18 -24 7 -43 -43 NIA N/A
14 300 14 14 -21 6 -56 -52 3955.8 105.55
15 300 16 16 -21 6 -25 -32 1964.9 33.2
16 300 20 20 -10 6 -25 -25 3172.05 107.65
17 300 21 21 -10 6 -25 -20 598.85 0.75
18 300 25 25 0 6 +84 67 NIA N/A
19 300 14 14 0 6 -2 -5 212.35 0
 
20 150 17 12 -20 (at 6 days) 6 -54 refused 1170.75 5.65
21 300 17 15 -13 (at 6 days) 6 -54 refused 3775.85 101.75
22 300 17 11 Not measurable 9 -52 off protocol-no longer a candidate for surgery N/A  
23 150 15 4 Removed from the protocol due to tumor complications N/A  
24 Removed from the protocol due to non-compliance N/A  

Pink - patients receiving 150 mg erlotinib; Cyan - patients receiving 300 mg erlotinib; Gray- patients without post-treatment PET/CT. N/A Not Available.